Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AbbVie Makes Further Inroads In Oncology As Humira Loss Looms

Executive Summary

New data position BCL-2 inhibitor Venclexta, partnered with Roche, for roles in multiple myeloma and acute myeloid leukemia, among other indications beyond chronic lymphocytic leukemia.

You may also be interested in...



Veliparib Phase III Failures Strike Blow To AbbVie's Oncology Strategy

The failure of veliparib in Phase III studies of squamous NSCLC and triple-negative breast cancer is a blow for AbbVie's oncology pipeline, but may not have implications for other PARP inhibitors in new tumor types.

Lynparza's Wider Prospects Boosted By Late-Stage Breast Cancer Study

Hopes for wider use of AstraZeneca Lynparza (olaparib) were boosted by Phase III data showing improved survival rates in patients with a certain type of breast cancer who used the PARP inhibitor compared with chemotherapy alone.

Keeping Track: Trulance Is First Novel Drug Of 2017; Vantrela ER Is Year's Second Abuse-Deterrent Opioid

The latest drug development news and highlights from our FDA Performance Tracker.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

MT142639

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel